Idioma:

Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies

Shiu, K-K ; Wetterskog, D ; Mackay, A ; Natrajan, R ; Lambros, M ; Sims, D ; Bajrami, I ; Brough, R ; Frankum, J ; Sharpe, R ; Marchio, C ; Horlings, H ; Reyal, F ; van der Vijver, M ; Turner, N ; Reis-Filho, J S ; Lord, C J ; Ashworth, A

Oncogene, 2014-01, Vol.33 (5), p.619-631 [Periódico revisado por pares]

England: Nature Publishing Group

Texto completo disponível

Citações Citado por

Enviar para

Título:
Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies
Autor: Shiu, K-K ; Wetterskog, D ; Mackay, A ; Natrajan, R ; Lambros, M ; Sims, D ; Bajrami, I ; Brough, R ; Frankum, J ; Sharpe, R ; Marchio, C ; Horlings, H ; Reyal, F ; van der Vijver, M ; Turner, N ; Reis-Filho, J S ; Lord, C J ; Ashworth, A
Assuntos: Breast cancer ; Breast Neoplasms - genetics ; Breast Neoplasms - metabolism ; Cell Line, Tumor ; Female ; Gene Amplification - genetics ; Gene expression ; Gene Expression Profiling ; Genetic aspects ; Health aspects ; Humans ; Hybridization ; Kinases ; MCF-7 Cells ; Oncology ; Receptor, ErbB-2 - biosynthesis ; Receptor, ErbB-2 - genetics ; Receptor, ErbB-2 - metabolism ; RNA Interference ; RNA, Small Interfering ; Studies ; Transcription Factor AP-2 - biosynthesis ; Transcription Factor AP-2 - metabolism
É parte de: Oncogene, 2014-01, Vol.33 (5), p.619-631
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
Descrição: Overexpression of the receptor tyrosine kinase ERBB2 (also known as HER2) occurs in around 15% of breast cancers and is driven by amplification of the ERBB2 gene. ERBB2 amplification is a marker of poor prognosis, and although anti-ERBB2-targeted therapies have shown significant clinical benefit, de novo and acquired resistance remains an important problem. Genomic profiling has demonstrated that ERBB2+ve breast cancers are distinguished from ER+ve and 'triple-negative' breast cancers by harbouring not only the ERBB2 amplification on 17q12, but also a number of co-amplified genes on 17q12 and amplification events on other chromosomes. Some of these genes may have important roles in influencing clinical outcome, and could represent genetic dependencies in ERBB2+ve cancers and therefore potential therapeutic targets. Here, we describe an integrated genomic, gene expression and functional analysis to determine whether the genes present within amplicons are critical for the survival of ERBB2+ve breast tumour cells. We show that only a fraction of the ERBB2-amplified breast tumour lines are truly addicted to the ERBB2 oncogene at the mRNA level and display a heterogeneous set of additional genetic dependencies. These include an addiction to the transcription factor gene TFAP2C when it is amplified and overexpressed, suggesting that TFAP2C represents a genetic dependency in some ERBB2+ve breast cancer cells.
Editor: England: Nature Publishing Group
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies

Shiu, K-K ; Wetterskog, D ; Mackay, A ; Natrajan, R ; Lambros, M ; Sims, D ; Bajrami, I ; Brough, R ; Frankum, J ; Sharpe, R ; Marchio, C ; Horlings, H ; Reyal, F ; van der Vijver, M ; Turner, N ; Reis-Filho, J S ; Lord, C J ; Ashworth, A

England: Nature Publishing Group

Buscando em bases de dados remotas. Favor aguardar.